Financial Planning Hawaii Inc. Makes New $679,000 Investment in Merck & Co., Inc. $MRK

Financial Planning Hawaii Inc. bought a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,446 shares of the company’s stock, valued at approximately $679,000.

Several other large investors have also recently made changes to their positions in the business. Darwin Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 237.4% in the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after buying an additional 216 shares during the last quarter. Kilter Group LLC bought a new position in Merck & Co., Inc. during the 2nd quarter valued at approximately $27,000. Bare Financial Services Inc raised its stake in Merck & Co., Inc. by 51.9% during the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after buying an additional 125 shares during the last quarter. Barnes Dennig Private Wealth Management LLC raised its stake in Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after buying an additional 266 shares during the last quarter. Finally, Evolution Wealth Management Inc. bought a new stake in Merck & Co., Inc. in the second quarter worth $31,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Late‑stage cholesterol pill delivered large LDL cuts (≈64.6%) and met its head‑to‑head primary endpoint — a potential new blockbuster oral option for lowering “bad” cholesterol that could materially diversify revenue beyond oncology. Merck’s drug reduced bad cholesterol by 64.6% in late-stage trial
• Positive Sentiment: Phase 2 CADENCE results for WINREVAIR (sotatercept-csrk) showed proof‑of‑concept in combined post‑ and precapillary pulmonary hypertension with HFpEF — opens a foothold in a hard heart‑failure segment and supports pipeline value. How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” and a $142 price target — a sizable upside vs. current levels that can support investor confidence and buying interest. Benzinga coverage
• Neutral Sentiment: Retail and media attention (e.g., Jim Cramer’s “stay the course” call) has driven momentum into Merck stock over recent months; that attention can amplify swings but is not a fundamental catalyst. Merck (MRK) Shares Up Significantly Since Jim Cramer Advised to “Stay the Course”
• Neutral Sentiment: Industry reports list Merck as a major player in the growing cutaneous squamous cell carcinoma market — underscores long‑term TAM but not an immediate stock driver. Cutaneous Squamous Cell Carcinoma (cSCC) Market Rises to $8.33 Billion
• Neutral Sentiment: New FY2026 earnings estimates and coverage updates are circulating (Erste Group Bank note) — watch revisions for guidance confirmation versus management’s FY2026 EPS range. FY2026 Earnings Estimate for MRK Issued By Erste Group Bank
• Negative Sentiment: Analysis flags an upcoming Keytruda patent cliff and Merck’s aggressive M&A push to refill the revenue gap — a strategic risk that could pressure sentiment if deal execution or integration falls short. Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on MRK shares. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday. The Goldman Sachs Group upped their price target on shares of Merck & Co., Inc. from $92.00 to $120.00 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research note on Friday, February 13th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $127.13.

Merck & Co., Inc. Stock Down 1.4%

Merck & Co., Inc. stock opened at $117.99 on Tuesday. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14. The stock has a fifty day simple moving average of $116.83 and a two-hundred day simple moving average of $102.29. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The firm has a market cap of $291.71 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 2.31 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same period in the prior year, the company posted $1.72 earnings per share. The company’s quarterly revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be paid a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Insider Buying and Selling at Merck & Co., Inc.

In other news, CEO Robert M. Davis sold 47,434 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the sale, the chief executive officer owned 443,602 shares of the company’s stock, valued at $52,362,780.08. This trade represents a 9.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Richard R. Deluca sold 37,685 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the sale, the executive vice president owned 160,174 shares of the company’s stock, valued at $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.09% of the stock is owned by company insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.